Released Mar 5, 2021, before the open
10-K filed Mar 5, 2021, 64 days after period end · 0001564590-21-011110
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$8.39M-$8.39M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$7,950,000N/M
Operating Cash Flowderived-$6,573,000N/M
Free Cash Flowderived-$6,656,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|
| Net Income | -$8.39M | -$11.68K |
| EPS Diluted | — | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR